In a report published Wednesday, Oppenheimer analyst Ling Wang initiated coverage on Rockwell Medical RMTI with an Outperform rating and $24.00 price target.
In the report, Oppenheimer noted, “We are initiating coverage on RMTI with an Outperform rating and price target of $24. We expect RMTI shares to have significant upside to be driven by the potential regulatory approval of Triferic™ as iron replacement therapy for chronic kidney disease (CKD) patients on hemodialysis in 1Q15, possible market launch of both Triferic™ and Calcitriol in 1H15 and significant top and bottom line growth (we project RMTI reaching profitability in 2015 assuming Triferic™ approval).”
Rockwell Medical closed on Tuesday at $9.51.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in